In contrast to allogeneic hematopoietic stem cell transplantation, the current dogma is not an evidence of graft-versus-tumor effect in autologous hematopoietic stem cell transplantation; thus, it is assumed that autologous hematopoietic stem cell transplantation only relies on the high-dose chemotherapy to improve clinical outcomes. However, recent studies argue in favor of the existence of an...

Background: Burkitt lymphoma is a common subtype of non-Hodgkin lymphoma in children. It has a rapid and aggressive clinical course with frequent involvement of bone marrow and central nervous system. Systemic chemotherapy is the mainstay of the treatment for this malignancy in children. In this systematic review, we discuss autologous and allogeneic hematopoietic stem cell transplantation (HSC...

Unlike in adults, the number of pediatric autologous hematopoietic stem cell transplants (HSCT) has decreased last years. This is because changing indications for this type treatment and new therapies available recent Polish HSCT centers have followed published recommendations Pediatric Hematopoietic Stem Cell Transplantation Group, which are generally based on European Society Blood Marrow ind...

post-remission treatment in patients with acute myeloid leukemia is still controversial. one potent choice for patients with no donor available is autologous stem cell transplantation. the median follow-up period was 18 months and the median age was 26 years old. in the review of 116 recently diagnosed aml patients (except aml- m3) who underwent autologous stem cell transplantation, 72.4% of pa...

• About Solid Tumours • Cancer Basics • Causes, risk factors and staging • Treatment • How are Stem Cells Helping in the battle against solid tumours? • History of hematopoietic stem cell transplantation (HSCT) • Autologous versus allogeneic HSCT • Allogeneic stem cell transplants – graft versus tumour effect • Autologous HSCT for solid tumours • Research and clinical directions • Hematopoietic...

Citation: Pockley AG, Lindsay JO, Foulds GA, Rutella S, Gribben JG, Alexander T and Snowden JA (2018) Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn’s Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD— Low Intensity Therapy Evaluati...

introduction: allogeneic hematopoietic cell transplantation (hsct) is the only therapeutic modality capable of correcting the hematologic manifestations of fanconi anemia (fa). the development  of well  tolerated,  immunosuppressive  conditioning  regimens  for fa patients  undergoing hsct has proven to be a rather challenging task for hematologists. methods: we analyzed the outcome of 30 fa pa...

conclusions in iran, hsct has been successfully adapted in routine clinical care. recently, new methods such as double cord blood and haploidentical transplantation have been used to treat many life-threatening diseases. results about 78.2% of the patients (2530 of 3237) remained alive between one to 211 months after stem cell transplantation. nearly, 21.8% (707) of our patients died after stem...

Autologous hematopoietic stem cell transplantation has proved to be an effective treatment for certain hematologic malignancies. However, relapse rates are high during the first year after transplantation. These relapses are attributed to the failure of high-dose chemotherapy to eradicate minimal residual malignant disease. In allogeneic hematopoietic stem cell transplantation, the higher antit...

the increased risk of hemolytic reactions and erythrocyte recovery delay in abo incompatible hematopoietic stem cell transplantation (hsct) is well established. effects of abo incompatibility on transplantation outcomes is evaluated in this study. we prospectively followed 501 patients undergoing allogeneic stem cell transplantation according to abo compatibility groups of minor, major and bidi...